Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

With the stock currently trading at Rs 405.05, Biocon has demonstrated strong financial performance and positive investor sentiment, as reflected by its 52-week high and bullish market outlook.

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of Novo Nordisk A/S's Ozempic and Wegovy ...

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...

When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd ...

Biocon Biologics, a unit of Biocon , opens new tab, said Hulio would be available at a list price of 5% below Humira's current list price. Humira comes at list price of $6,922 per carton.

Biocon and Viatris expect to close the transaction in the second half of this year. When it happens, Viatris will have one nominee on the Biocon board of directors.